Psychotherapy in social anxiety disorder and alterations in neural processing (PANDA) – pilot study - PANDA-Pilot

AB Klinische Psychologie und Psychotherapie, FB Erziehungswissenschaft und Psychologie, Freie Univerisät Berlin0 sites60 target enrollmentMarch 5, 2020

ConditionsF40.1 Social phobias

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: F40.1
Sponsor: AB Klinische Psychologie und Psychotherapie, FB Erziehungswissenschaft und Psychologie, Freie Univerisät Berlin
Enrollment: 60
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 5, 2020

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

AB Klinische Psychologie und Psychotherapie, FB Erziehungswissenschaft und Psychologie, Freie Univerisät Berlin

Eligibility Criteria

Inclusion Criteria

•We will recruit participants between 18\-65 years, from a patient population that is diagnosed with social anxiety disorder (F40\.1\). Participants will be diagnosed according to DSM\-5 criteria, based on the SKID\-I, axis 1: anxiety disorder section. Participants from the healthy control will be between 18\-65 years old and will be included if they do not suffer under any mental disorder according to DSM\-5 criteria.

Exclusion Criteria

•Participants will be excluded if they suffer from a current severe depression with or without psychotic symptoms (F32\.2, F32\.3, F33\.2 or F33\.3\), current borderline or antisocial personality disorder, current suicidality, current life\-time schizophrenic spectrum disorder, manic disorder (F2x.x) and bipolar (F31\.x), current substance dependency (alcohol, heroin, amphetamin, cocain; at least 12 months), current severe neurological disorder of the central nervous system, severe chronic obstructive pulmonary disease (COPD), cardiac disease, Body Mass Index \>35 or \<18, pregnancy, speaking impairment, non\-correctible vision and hearing impairments, regular intake of benzodiazepinen or Betablocker within the last 7 days, Tricyclic antidepressant with a dosage of \> 50mg per day, neuroleptics with a dosage of \> 30% of the daily dosage.